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Oxaliplatin is a chemotherapeutic agent that is effective against various types of cancer including
colorectal cancer. Acute cold hyperalgesia is a serious side effect of oxaliplatin treatment. Although the
therapeutic drug pregabalin is beneﬁcial for preventing peripheral neuropathic pain by targeting the
voltage-dependent calcium channel a2d-1 (Cava2d-1) subunit, the effect of oxaliplatin-induced acute cold
hypersensitivity is uncertain. To analyze the contribution of the Cava2d-1 subunit to the development of
oxaliplatin-induced acute cold hypersensitivity, Cava2d-1 subunit expression in the rat spinal cord was
analyzed after oxaliplatin treatment. Behavioral assessment using the acetone spray test showed that
6 mg/kg oxaliplatin-induced cold hypersensitivity 2 and 4 days later. Oxaliplatin-induced acute cold
hypersensitivity 4 days after treatment was signiﬁcantly inhibited by pregabalin (50 mg/kg, p.o.). Oxa-
liplatin (6 mg/kg, i.p.) treatment increased the expression level of Cava2d-1 subunit mRNA and protein in
the spinal cord 2 and 4 days after treatment. Immunohistochemistry showed that oxaliplatin increased
Cava2d-1 subunit protein expression in superﬁcial layers of the spinal dorsal horn 2 and 4 days after
treatment. These results suggest that oxaliplatin treatment increases Cava2d-1 subunit expression in the
superﬁcial layers of the spinal cord and may contribute to functional peripheral acute cold
hypersensitivity.
© 2016 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Oxaliplatin, a platinum-based chemotherapeutic drug, is widely
used for the treatment of various types of cancer including colo-
rectal cancer. Oxaliplatin plus capecitabine (XELOX) has been
established as adjuvant therapy for stage II/III colon cancer. How-
ever, its major dose-limiting side effect is peripheral sensory neu-
ropathy, which is characterized by paresthesia or dysesthesiaPharmacology, Showa Phar-
n, Machida, Tokyo 194-8543,
rmacological Society.
. Production and hosting by Elsetriggered by exposure to cold (1,2). Oxaliplatin-induced neurotox-
icity manifests as rapid-onset neuropathic symptoms that are
exacerbated by cold exposure and as chronic neuropathy that de-
velops after several treatment cycles (3,4). The symptoms of
oxaliplatin-induced acute peripheral neuropathy occur in 85e95%
of patients within hours of infusion (1).
Voltage-dependent calcium channels (VDCCs) have emerged as
potential ion channel targets for the treatment of neuropathic pain
(5,6). VDCCs are composed of a main pore-forming a1 subunit,
together with auxiliary a2d, b, and g subunits. VDCC alpha-2-delta-
1 (Cava2d-1) subunit protein and mRNA are upregulated in dorsal
root ganglia (DRGs) in models of peripheral nerve injury (7). Pre-
vious reports have suggested that peripheral nerve injury induces
upregulation of Cava2d-1 subunit protein in the dorsal spinal cordvier B.V. This is an open access article under the CC BY-NC-ND license (http://
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1 subunit protein is upregulated in superﬁcial layers of the dorsal
horn after spinal nerve ligation-induced nerve injury (9,10).
Moreover, Cava2d-1 subunit expression levels are signiﬁcantly
increased in the dorsal, but not ventral, spinal cord following spinal
cord injury (11). Increased Cava2d-1 subunit expression is observed
in the dorsal horn in a rat model of chemotherapy-evoked painful
peripheral neuropathy (12). Increased Cava2d-1 subunit expression
in the spinal cord after spinal cord injury and the neuropathic pain
model is likely an important mediator of pain maintenance and
development.
Binding of pregabalin, a structural analog of gabapentin, to the
Cava2d-1 subunit may be responsible for its efﬁcacy in the treat-
ment of neuropathic pain (10,13) and may play a key role in this
inhibitory action in chemotherapy-induced peripheral neuropathy.
Pregabalin is now commonly used to treat neuropathic pain in
rodent models and patients (14,15). However, the participation of
the Cava2d-1 subunit in oxaliplatin-induced acute cold hypersen-
sitivity remains unclear. Accordingly, we hypothesized that acute
cold hypersensitivity after oxaliplatin treatment is mediated by
upregulation of the Cava2d-1 subunit in the spinal cord. To test this
hypothesis, using a rat model of oxaliplatin-induced acute cold
hypersensitivity, we investigated the effects of oxaliplatin treat-
ment on Cava2d-1 subunit expression in the spinal cord and the
mediators of pain perception, and whether pregabalin alters acute
cold hypersensitivity after oxaliplatin treatment.
2. Materials and methods
2.1. Experimental animals
Male Wistar rats weighing 240e330 g were used in the present
study. All rats were housed individually under automatically
controlled environmental conditions using a 12-h lightedark cycle
(lights on from 08:00 to 20:00) with free access to food and water.
All animals were quarantined in centralized animal facilities for at
least 7 days upon arrival. Each animal was used only once. Exper-
iments were carried out according to the guidelines for animal care
and use published by the National Institutes of Health and the
committee of Showa Pharmaceutical University.
2.2. Drugs
One dose (6mg/kg) of oxaliplatin (Elplat®) was intraperitoneally
(i.p.) administered (Yakult Co., Ltd., Tokyo, Japan). Oxaliplatin was
dissolved in a 5% glucose solution at a concentration of 2 mg/ml.
The volume injected depended on the animal's weight to ensure i.p.
injections of less than 2.5 ml. The control rats were injected by the
same routewith 5% glucose solution according to a volume that was
adjusted to the weight of each rat. Pregabalin (SigmaeAldrich Inc.,
St. Louis, MO) was administered orally (p.o.; 50 mg/kg) 4 days after
oxaliplatin administration. All other chemicals and materials were
purchased from standard sources and were of reagent grade or
higher.
2.3. Acetone spray test for acute cold hypersensitivity
Observers blinded to the experimental conditions tested the rats
with the acetone spray test at the same time on days 0, 2, 4, and 7
after oxaliplatin treatment. To estimate cold sensitivity of both hind
paws, acetone (Kanto Chemical Co., Inc., Tokyo, Japan) was used
following modiﬁcation of previously described methods (16). Rats
were placed in a clear plastic box (23  23  12 cm) with a wire
mesh ﬂoor and allowed to habituate for 30 min prior to testing.
After habituation, 50 ml ﬂuid (acetone) was sprayed on the plantarsurface of the hind paws using a MicroSprayer® (Penn Century Inc.,
Philadelphia, PA). Paw withdrawal response, deﬁned as ﬂinching,
licking, or biting of the limb, was measured within 1 min after the
start of the acetone spray. The acetone spray test was performed
alternately ﬁve times for each hind paw, and the paw withdrawal
response was expressed as an overall percentage response. The
effects of the acetone spray were repeatedly evaluated over time
after oxaliplatin (6 mg/kg) or 5% glucose administration.
2.4. Semi-quantitative reverse transcription polymerase chain
reaction (RT-PCR)
Rats were deeply anesthetized with pentobarbital (50 mg/kg,
i.p.) on days 1, 2, 4, or 7 after the start of oxaliplatin (6 mg/kg, i.p.),
and the spinal cord (L4e6) was removed. Total RNA was extracted
using the NucleoSpin® RNA II kit (MACHEREY-NAGEL GmbH & Co.
KG, Düren, Germany). RT-PCR was performed as follows using the
PrimeScript® RT-PCR kit (Takara Bio Inc., Kusatsu, Japan) according
to the manufacturer's instructions. Complementary DNA (cDNA)
was synthesized from 1 mg total RNA with PrimeScript RTase using
an Oligo dT Primer at 42 C for 30 min. Each cDNAwas subjected to
PCR ampliﬁcation using gene-speciﬁc primers. b-actin expression
was used as an internal control in RT-PCR. The primer sequences for
ampliﬁcation of Cava2d-1 and b-actin were as follows: Cava2d-1
(forward) 50-GAACTCAACTGGACAAGTGCCT-30; Cava2d-1 (reverse)
50-CCATCCACTGAATAGGTCCTC-30; b-actin (forward) 50-GGGTATG-
GAATCCTGTGGCA-30; b-actin (reverse) 50-CGCAGCTCAGTAA-
CAGTCCG-30. Ampliﬁcation conditions were: pre-denaturation for
1 min at 94 C, denaturation for 30 s at 94 C, renaturation for 30 s
at 55 C, and extension for 1 min at 72 C. Aliquots of the RT-PCR
products were separated on a 1% agarose gel and visualized with
ethidium bromide. The PCR bands were quantiﬁed and normalized
to the control bandwith ImageJ (National Institutes of Health Image
software, version 1.35d, Bethesda, MD).
2.5. Western blot analysis
On days 2, 4, and 7 after oxaliplatin (6 mg/kg, i.p.) administra-
tion, rats were deeply anesthetized with pentobarbital (50 mg/kg,
i.p.). Spinal cords (L4e6) were removed and homogenized in cold
extraction buffer consisting of 10 mM TriseHCl buffer at pH 7.5,
100 mM NaCl, 1 mM EDTA, 0.5% Triton X-100, and 0.5% deoxy-
cholate. The homogenates were centrifuged for 30 min at
15,000 g at 4 C, and the supernatant was collected. Total protein
in the supernatant (30 mg) was electrophoresed on an
SDS-polyacrylamide gel (7.5%), and separated proteins were
transferred to polyvinylidene ﬂuoride membranes. Anti-Cava2d-1
antibody (Alomone Labs, Jerusalem, Israel; 1:200) was used, and
anti-b-actin antibody (SigmaeAldrich) was used as an internal
control. Horseradish peroxidase-labeled anti-rabbit antibody
(1:2000) was used as the secondary antibody (SigmaeAldrich).
Speciﬁc bands were detected using enhanced chemiluminescence
plus the TM Western Blotting Detection Kit (GE Healthcare, Buck-
inghamshire, UK) according to the manufacturer's protocol. The
intensities of immunoreactive bands were analyzed with Multi-
Gage Ver.3 software (Fuji Film, Tokyo, Japan).
2.6. Immunohistochemistry
Rats were deeply anesthetized with sodium pentobarbital
(50 mg/kg, i.p.) and perfused transcardially with 20 ml potassium-
free phosphate-buffered saline (Kþ-free PBS; pH 7.4) followed by
50 ml of 4% paraformaldehyde solution. The spinal cord (L4e6) was
removed, post-ﬁxed for 3 h, cryoprotected overnight in 25% sucrose
solution, and stored at80 C until use. Spinal cords were cut at 10-
Fig. 1. Time course of acute cold hypersensitivity after oxaliplatin administration. (A)
The acetone spray test was used to measure the acute cold response in rats on days
0 (before administration), 2, 4, and 7 after oxaliplatin administration (6 mg/kg, i.p.).
Data are the mean ± SEM of n ¼ 6 rats. *P < 0.05, **P < 0.01, Two-way ANOVA, followed
by Student's or Aspin-Welch's t-test was used. (B) Effect of pregabalin treatment on
oxaliplatin-induced acute cold hypersensitivity in rats. Behavioral responses of pre-
gabalin (50 mg/kg, p.o.) on acute cold hypersensitivity induced by oxaliplatin treat-
ment (6 mg/kg) on day 4. Graph shows the mean ± SEM of the response frequency to
cold stimulation by the acetone spray test. Oxaliplatin-induced acute cold hypersen-
sitivity was signiﬁcantly inhibited by pretreatment with pregabalin. n ¼ 6 per group.
**P < 0.01 vs. 5% glucose (vehicle), ##P < 0.01 vs. oxaliplatin. Statistical analysis was
performed using one-way ANOVA with the TukeyeKramer method.
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dried overnight at room temperature. Spinal cord sections were
incubated with excess blocking buffer containing 2% skim milk in
0.1% Triton X-100 in Kþ-free PBS and subsequently reacted over-
night at 4 C with anti-Cava2d-1 subunit antibodies (Sigma-
eAldrich, 1:200) in 2% bovine serum albumin/0.1% Triton X-100 in
Kþ-free PBS. The sections were then incubated in ﬂuorescein
isothiocyanate-conjugated anti-rabbit IgG (SigmaeAldrich, 1:200)
for 2 h at room temperature. The immunostained sections were
treated with Permaﬂuor™ (Thermo Shandon, Pittsburgh, PA),
mounted on slides, covered with microslips, and observed with an
Olympus laser-scanning confocal microscope (FLUOVIEW BW50,
Olympus, Tokyo, Japan) at a wavelength of 495 nm. A total of ﬁve
sections (90 mm apart) were randomly selected from each spinal
cord. Optical density (OD) of the stained sites was determined with
the ImageJ program using a computer. The OD of superﬁcial layers
of the spinal cord was calculated for day 4 after oxaliplatin
treatment.
2.7. Statistical analysis
All data are expressed as themean± SEM. In thebehavioral study,
the signiﬁcance of the difference in the response rate between
vehicle and oxaliplatin was calculated using two-way analysis of
variance (ANOVA) followed by the Student's or Aspin-Welch's t-test.
The signiﬁcance of thedifference among thevehicle, oxaliplatin, and
pregabalin groups was calculated using one-way ANOVA followed
by the TukeyeKramer method. The statistical signiﬁcance of dif-
ferences in other experiments was analyzed using one-way ANOVA
followed by Dunnett's multiple comparison test. Immunohisto-
chemical staining data are shown as the percentage of OD obtained
from each oxaliplatin-treated rat (OD data on day 0 were deﬁned as
100%). Statistical signiﬁcance was accepted at P < 0.05.
3. Results
3.1. Effects of oxaliplatin on acute cold hypersensitivity
We ﬁrst investigated the effect of oxaliplatin (6 mg/kg, i.p.,
n ¼ 6) on acute cold hypersensitivity. Before the single dose of
oxaliplatin (day 0), we found no signiﬁcant differences in the
number of withdrawal responses in any groups in the acetone spray
test. The withdrawal response rate with the acetone spray test was
signiﬁcantly increased (F[3,40] ¼ 3.69, P < 0.05) with 6 mg/kg
oxaliplatin at 2 days (day 2) and 4 days (day 4) after a single dose of
oxaliplatin compared to 5% glucose treatment (Fig. 1A). This
oxaliplatin-induced acute cold hypersensitivity decreased gradu-
ally up to 7 days (day 7) after the treatment.
3.2. Effect of pregabalin on oxaliplatin-induced acute cold
hyperalgesia
The effects of pregabalin on oxaliplatin-induced (6 mg/kg i.p.,
n¼6) acute coldhyperalgesia are shown in Fig.1B. Administrationof
pregabalin (50 mg/kg p.o., n ¼ 6) 30 min before the acetone test
signiﬁcantly inhibited acute cold hypersensitivity on day 4
compared to oxaliplatin treatment alone (F ¼ 16.17, P < 0.01). Thus,
pregabalin reversedoxaliplatin-inducedacute coldhypersensitivity.
3.3. Effect of oxaliplatin on expression of Cava2d-1 subunit mRNA in
the spinal cord
We investigated the expression of Cava2d-1 subunit mRNA
during cold hypersensitivity after oxaliplatin administration. We
removed the spinal cord on days 0, 2, 4, and 7 after administrationof 6 mg/kg oxaliplatin, and Cava2d-1 subunit mRNA expression was
quantiﬁed with RT-PCR. As shown in Fig. 2, 6 mg/kg oxaliplatin
signiﬁcantly increased Cava2d-1 subunit mRNA expression
(F ¼ 3.93, P < 0.05) in the spinal cord on day 2 (119.0 ± 2.9%, n ¼ 5,
P< 0.05) and day 4 (138.5± 13.9%, n¼ 5, P < 0.05). Cava2d-1 subunit
mRNA expressionwas signiﬁcantly increased andmaximal on day 4
and returned to control levels 7 days after administration of oxa-
liplatin (Fig. 2).
3.4. Effect of oxaliplatin treatment on Cava2d-1 subunit protein in
the spinal cord
We removed the spinal cord on days 0, 2, 4, and 7 after
administration of 6 mg/kg oxaliplatin treatment, and Cava2d-1
subunit protein expressionwas quantiﬁed by western blot analysis.
As shown in Fig. 3, 6 mg/kg oxaliplatin treatment signiﬁcantly
increased Cava2d-1 subunit protein expression (F ¼ 6.52, P < 0.01)
in the spinal cord on day 2 (184.3 ± 18.5%, n¼ 5, P < 0.01) and day 4
(218.6 ± 26.9%, n ¼ 5, P < 0.01). A signiﬁcant increase in Cava2d-1
Fig. 2. Oxaliplatin administration increases voltage-dependent calcium channel sub-
unit a2d-1 (Cava2d-1) mRNA in the spinal cord. Effect of oxaliplatin (6 mg/kg, i.p.) on
Cava2d-1 subunit mRNA expression in the rat spinal cord (L4e6) on days 0 (before
administration), 2, 4, and 7 was measured. Histograms show the relative amount of
Cava2d-1 subunit mRNA in oxaliplatin-treated rats compared with day 0. Data are the
mean ± SEM. n ¼ 5 for oxaliplatin administration. *P < 0.05, versus day 0. Statistical
analysis was performed using one-way ANOVA followed by Dunnett's multiple com-
parison test.
Fig. 3. Effect of oxaliplatin on Cava2d-1 subunit protein expression in the rat spinal
cord (L4e6). Cava2d-1 subunit and b-actin protein in the spinal cord on days 0 (before
administration), 2, 4, and 7 was measured. Cava2d-1 subunit protein expression was
normalized to b-actin expression. Histograms show the relative amount of Cava2d-1
subunit protein in oxaliplatin-treated (6 mg/kg, i.p.) rats. The western blot shows
representative data. Data are the mean ± SEM. n ¼ 5, **P < 0.01 versus day 0. Statistical
analysis was performed using one-way ANOVA followed by Dunnett's multiple com-
parison test.
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compared to day 0 values, and expression returned to control levels
7 days after administration of oxaliplatin (Fig. 3).3.5. Immunohistochemistry
Immunohistochemistry revealed that most of the Cava2d-1 sub-
unitprotein in the spinal cordwas localized in superﬁcial layers of the
spinal dorsal horn (Fig. 4A). Using computerized OD image analysis,
we found that superﬁcial layers of the spinal cord were positivelylabeled for the Cava2d-1 subunit protein in rats. As shown in Fig. 4B,
6 mg/kg oxaliplatin treatment signiﬁcantly increased the OD per-
centage (F ¼ 4.01, P < 0.05) in superﬁcial layers of the spinal dorsal
hornonday 2 (130.6±16.1%, n¼ 5, P<0.01) andday 4 (143.1±12.2%,
n¼ 5, P< 0.01). Thus, oxaliplatin-induced (6mg/kg) enhancement of
Cava2d-1 subunit protein expression resulted from upregulation of
expression in superﬁcial layers of the spinal dorsal horn.
4. Discussion
Our present study indicated that single administration of oxa-
liplatin produced acute cold hypersensitivity in rats that was
attenuated by pregabalin. In previous experimental studies, single
or multiple doses of oxaliplatin produce acute cold allodynia and
cold hypersensitivity (17e19). Also, using the acetone spray test,
our previous study showed that oxaliplatin induces acute cold
hypersensitivity in a dose-dependent manner (20). Thus, the re-
sults of our study agree with these previously published ﬁndings
(4,21).
We ﬁrst demonstrated that oxaliplatin treatment (6 mg/kg)
signiﬁcantly increased the expression of Cava2d-1 mRNA and pro-
tein in the rat spinal cord, and immunohistochemistry revealed
that this Cava2d-1 protein expression was increased in superﬁcial
layers of the spinal cord. Increased Cava2d-1 expression in a
transgenicmouse line leads to dorsal horn neuron hyperexcitability
(8,22). Cava2d-1 subunit expression is upregulated in the spinal
cord following an experimental nerve crush injury (23,24). This
upregulation correlates with the onset of allodynia, in which the
sensation of non-noxious touch causes pain-related behaviors.
These data suggest that the upregulation of Cava2d-1 subunits in
the spinal cord may contribute to oxaliplatin treatment-induced
acute cold hypersensitivity.
Pregabalin, a structural analog of gabapentin, is a ligand at the
Cava2d-1 subunit, and binding at this site reduces calcium inﬂux
into nerve terminals and consequently reduces neurotransmission
(25e28). Previous reports have shown that pregabalin alleviates
neuropathic pain such as pain caused by peripheral nerve ligation
and diabetic neuropathic pain in various models (29,30). Intrathe-
cally administered pregabalin attenuates cold allodynia in the
acetone test in a dose-dependent manner in neuropathic pain
models (32). Clinically, pregabalin signiﬁcantly reduces the severity
of oxaliplatin-induced sensory neuropathy in patients (15). In the
present study, we observed that administration of pregabalin
completely reversed oxaliplatin-induced acute cold hypersensitiv-
ity. Recently, we reported that paclitaxel treatment increases VDCC
current in small- and medium-diameter rat DRG neurons and
upregulates Cava2d-1 subunit protein expression in DRGs (31).
Cava2d-1 mRNA and protein are also increased in DRGs following
paclitaxel treatment (33). Our current results show that oxaliplatin
treatment-induced increased expression of Cava2d-1 subunit pro-
tein in the spinal cord. Interestingly, Cava2d-1 subunit upregulation
following administration of oxaliplatin is similar to the increase in
Cava2d-1 subunits in the paclitaxel-induced neuropathic pain
model. Thus, this upregulation may be correlated with the onset of
oxaliplatin-induced acute cold hypersensitivity. Moreover, Bauer
et al. (10) reported the importance of trafﬁcking of the Cava2d-1
subunit from DRGs to the spinal dorsal horn during the develop-
ment of neuropathic pain and subsequent alleviation with pre-
gabalin. The efﬁcacy of pregabalin for alleviation of neuropathic
pain is due to binding to Cava2d-1 subunits (13). We hypothesize
that the superﬁcial layer of the spinal cord is an important site of
action for pregabalin, which may exert its antiallodynic effect
mainly on the spinal cord (32). In addition, pregabalin attenuates
spinal dorsal horn nociceptive responses in rat neuropathic pain
models (34). The antiallodynic effect of pregabalin is mainly
Fig. 4. Immunohistochemistry of Cava2d-1 protein expression in the spinal cord (L4e6) after oxaliplatin treatment. (A) Spinal cord sections (10 mm thick) from days 0 (before
administration), 2, 4, and 7 after oxaliplatin (6 mg/kg, i.p.) treatment were stained with antibodies against Cava2d-1 subunit protein. White dashed line demarcates the border of the
superﬁcial layers of the spinal cord. (B) Optical density (OD) of Cava2d-1 subunit-stained spinal cord sections on days 0 (before administration), 2, 4, and 7 after oxaliplatin (6 mg/kg,
i.p.) administration. The means ± SEM of the OD for Cava2d-1 subunit protein expression are indicated by the columns and vertical bars. n ¼ 5, **P < 0.01 versus day 0. Statistical
analysis was performed using one-way ANOVA followed by Dunnett's multiple comparison test.
K. Yamamoto et al. / Journal of Pharmacological Sciences 130 (2016) 117e122 121mediated by spinal mechanisms, although supraspinal or periph-
eral mechanisms cannot be excluded. Thus, the increased expres-
sion of Cava2d-1 subunits in the spinal dorsal horn is a main target
of the inhibitory action of pregabalin on oxaliplatin-induced acute
cold hypersensitivity. These results indicate that pregabalin is a
promising candidate drug for treatment of oxaliplatin-induced
peripheral neuropathy. Thus, the anti-hyperalgesic action of pre-
gabalin may be due to inhibition of increased Cava2d-1 subunit
protein expression following oxaliplatin treatment in the spinal
cord. Interestingly, pregabalin did not affect the results of the
acetone test in control rats treated with 5% glucose. Pregabalin
reduces the severity of oxaliplatin-induced sensory neuropathy
(15), and thus, we hypothesize that pregabalin may have a thera-
peutic effect when the Cava2d-1 subunit protein levels are elevated
in the spinal cord.
On the other hand, single administration of oxaliplatin (3mg/kg,
i.p.) signiﬁcantly increases expression of Cava2d-1 subunit mRNA in
the mouse DRG but not in the spinal cord (35). Our result showed
that Cava2d-1 subunit mRNA in the spinal cord was signiﬁcantly
increased 4 days after administration of oxaliplatin (6 mg/kg, i.p.).
Gauchan et al. (35) studied mice 10 days after intraperitoneal
administration of oxaliplatin, whereas our results were obtained 4
days after oxaliplatin treatment in rats. This may account for the
reported differences, because Cava2d-1 subunit mRNA levels in
neurons change over time. The different results between the two
studies may also be due to different dosages (3 mg/kg or 6 mg/kg).
In addition, our immunohistochemical results indicated that
Cava2d-1 protein was signiﬁcantly increased in superﬁcial layers of
the spinal cord 4 days after oxaliplatin treatment.
In conclusion, we show that single administration of oxaliplatin
increases Cava2d-1 subunit expression in superﬁcial layers of the
spinal cord. Moreover, pregabalin inhibits oxaliplatin-induced
acute cold hypersensitivity.Conﬂicts of interest
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